Overall, these results clearly demonstrated that polyamine synthesis is required for efficient KSHV lytic reactivation and de novo infection, and that FDA-approved drugs inhibiting the key enzyme ODC1 can be used to block KSHV lytic reactivation and the following viral dissemination. This evidence concerns the gene ODC1 and infection.